首页> 外文期刊>Interventional neuroradiology: journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences >Spanish Registry for Embolization of Small Intracranial Aneurysms with Cerecyte Coils (SPAREC) Study: Early Experience and Mid-Term Follow-up Results
【24h】

Spanish Registry for Embolization of Small Intracranial Aneurysms with Cerecyte Coils (SPAREC) Study: Early Experience and Mid-Term Follow-up Results

机译:西班牙颅内小动脉栓塞栓塞研究中心(SPAREC)研究:早期经验和中期随访结果

获取原文
获取原文并翻译 | 示例
           

摘要

This study aimed to report the results obtained in treating small ruptured and unruptu-red intracranial aneurysms using Cerecyte coils. A prospective, non-randomized multicenter registry operating in Spain with a reporting period between May 2005 and September 2007. We present clinical and angiographic results for 48 small aneurysms (26 ruptured, five with III cranial nerve paresis, and 17 incidental) that had undergone six months' follow-up. The volumetric percentage occlusion (VPO) achieved and percentage bioactive coils (PBC) used were assessed.No episodes of bleeding occurred during the follow-up period. The technical complication rate was 10.4% (five cases): four thromboem-bolic complications resolved with medication (8.3%) and one asymptomatic protrusion of a coil into the parent vessel. The clinical complication rate for the procedure was 2.1% (occlusion of the anterior choroidal artery in a ruptured anterior choroidal anaeurysm). Mean VPO was 25.2%. Balloon-assisted technique (BAT) was used in 60.4% of cases. The VPO was higher in the BAT-treated cases (P<0.05). The overall six-month recanalization rate was 16.7% (12.5% minor and 4.2% major recanalizations). Neck size and VPO were unrelated to the recanalization rate. The PBC was higher in cases with progressive Deployment of the device is safe from the standpoint of periprocedural technical and clinical complications. No episodes of hemorrhage were recorded during follow-up. The six-month recanalization and retreatment rates compared favorably with most endovascular platinum and bioactive coil series.
机译:这项研究旨在报告使用Cerecyte线圈治疗小破裂和未破裂红色颅内动脉瘤所获得的结果。一个在西班牙运营的前瞻性,非随机性的多中心注册中心,报告期为2005年5月至2007年9月。我们提供了48例小动脉瘤(26例破裂,5例颅脑轻瘫,5例偶发)的临床和血管造影结果。六个月的随访。评估达到的体积闭塞百分比(VPO)和使用的生物活性线圈(PBC)百分比。在随访期间未发生出血事件。技术并发症发生率为10.4%(5例):4例血栓栓塞性并发症通过药物治疗得以解决(8.3%),且无症状地将线圈卷入母脉。该手术的临床并发症发生率为2.1%(在破裂的前脉络膜动脉瘤中阻塞了前脉络膜动脉)。平均VPO为25.2%。在60.4%的病例中使用了气球辅助技术(BAT)。在BAT治疗的病例中,VPO较高(P <0.05)。六个月的总体再通率为16.7%(次要再通率12.5%,次要再通率4.2%)。颈部大小和VPO与再通率无关。从围手术期技术和临床并发症的角度来看,在逐步部署该装置的情况下,PBC较高。随访期间未记录出血事件。与大多数血管内铂和生物活性线圈系列相比,六个月的再通和再治疗率高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号